Viewing Study NCT04690322



Ignite Creation Date: 2024-05-06 @ 3:37 PM
Last Modification Date: 2024-10-26 @ 1:53 PM
Study NCT ID: NCT04690322
Status: RECRUITING
Last Update Posted: 2024-02-16
First Post: 2020-12-27

Brief Title: POCUS Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Sponsor: University of Texas Southwestern Medical Center
Organization: University of Texas Southwestern Medical Center

Study Overview

Official Title: POCUS Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
Status: RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a prospective randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy which are both standard of care treatment for persons with Hemophilia A
Detailed Description: This is a research study to find out if there is a difference in the way children with hemophilia A form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII based replacement therapy vs non-FVIII based replacement as part of their hemophilia treatment to prevent spontaneous joint bleeds

Both therapies are standard of care therapies for patients with hemophilia A The only experimentalresearch procedures as part of this study include the thrombin generation assay and ultrasound All other procedures are standard of care

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None